Nautilus Biotechnology is trading at $3.15, up 9.17%, after third-quarter results beat analyst expectations.
- October 28 gains extend the prior session’s 18.44% rise. The company reported a $0.12-per-share loss versus $0.14 expected and $230,000 revenue versus $206,250 forecast.
- Management reaffirmed Voyager’s mid-2027 instrument shipment timeline and raised 2026 revenue outlook above its prior approximately $500,000 forecast.
- Biotech-sector strength may add support; the earnings beat is the clearer company-specific catalyst.